Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 20;69(3):377-379.
doi: 10.1590/1806-9282.20221608. eCollection 2023.

Comprehensive assessment model for patients with spinal muscular atrophy: proposal of tools for clinical practice and real-world studies

Renalli Manuella Rodrigues Alves  1   2 , Vanessa Van Der Linden  3   4 , Lívia Barbosa de Andrade  1
Affiliations

Comprehensive assessment model for patients with spinal muscular atrophy: proposal of tools for clinical practice and real-world studies

Renalli Manuella Rodrigues Alves et al. Rev Assoc Med Bras (1992). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: the authors declare there is no conflicts of interest.

References

    1. Hjartarson HT, Nathorst-Böös K, Sejersen T. Disease modifying therapies for the management of children with spinal muscular atrophy (5q SMA): an update on the emerging evidence. Drug Des Devel Ther. 2022;16:1865–1883. doi: 10.2147/DDDT.S214174. - DOI - PMC - PubMed
    1. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197–207. doi: 10.1016/j.nmd.2017.11.004. - DOI - PubMed
    1. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(3):103–115. doi: 10.1016/j.nmd.2017.11.005. - DOI - PubMed
    1. Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol. 2022;39:1–10. doi: 10.1016/j.ejpn.2022.04.006. - DOI - PubMed
    1. Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155–161. doi: 10.1016/j.nmd.2009.11.014. - DOI - PMC - PubMed